Abstract:Background B cell translocation gene 1 ( BTG1 ) has long been recognized as a tumor suppressor gene. Recent reports demonstrated that BTG1 plays an important role in progression of cell cycle and is involved in cellular response to stressors. However, the microRNAs mediated regulatory mechanism of BTG1 expression has not been reported so far. MicroRNAs can effectively influence tumor radiosensitivity by preventing cell cycle progression, resulting in enhancement of the cytotoxicity of radiotherapy efficacy. This study aimed to demonstrating the effects of microRNAs on the BTG1 expression and cellular radiosensitivity. Methods The human renal carcinoma 786-O cells were treated with 5 Gy of X-rays. Expressions of BTG1 gene and miR-454-3p, which was predicted to target BTG1 by software algorithm, were analyzed by quantitative polymerase chain reaction. Protein expressions were assessed by Western blot. Luciferase assays were used to quantify the interaction between BTG1 3′-untranslated region (3′-UTR) and miR-454-3p. The radiosensitivity was quantified by the assay of cell viability, colony formation and caspase-3 activity. Results The expression of the BTG1 gene in 786-O cells was significantly elevated after treatments with X-ray irradiation, DMSO, or serum starvation. The up-regulation of BTG1 after irradiation reduced cellular radiosensitivity as demonstrated by the enhanced cell viability and colony formation, as well as the repressed caspase-3 activity. In comparison, knock down of BTG1 by siRNA led to significantly enhanced cellular radiosensitivity. It was found that miR-454-3p can regulate the expression of BTG1 through a direct interaction with the 3′-UTR of BTG1 mRNA. Decreasing of its expression level correlates well with BTG1 up-regulation during X-ray irradiation. Particularly, we observed that over-expression of miR-454-3p by transfection inhibited the BTG1 expression and enhanced the radiosensitivity. In addition, cell cycle analysis showed that over-expression of miR-454-3p shifted the cell cycle arrest from G2/M phase to S phase. Conclusions Our results indicate that BTG1 is a direct target of miR-454-3p. Down-regulation of BTG1 by miR-454-3p renders tumor cells sensitive to radiation. These results may shed light on the potential application in tumor radiotherapy.

BTG1 potentiates apoptosis and suppresses proliferation in renal cell carcinoma by interacting with PRMT1.

Expression of BTG1 in Renal Clear Cell Carcinoma and Its Role in 786-O Cell Proliferation and Apoptosis in Vitro

RCC1 functions as a tumor facilitator in clear cell renal cell carcinoma by dysregulating cell cycle, apoptosis, and EZH2 stability

Expression of BTG1 in HK-2 and 786-O and Its Influence on Cell Cycle and Apoptosis of HK-2 and 786-O

Btg1 Inhibits Breast Cancer Cell Growth Through Induction Of Cell Cycle Arrest And Apoptosis

Down-regulation of BTG1 by miR-454-3p enhances cellular radiosensitivity in renal carcinoma cells

The expression of BTG1 is downregulated in NSCLC and possibly associated with tumor metastasis

Upregulation of BTG1 Enhances the Radiation Sensitivity of Human Breast Cancer in Vitro and in Vivo

BTG1 Overexpression Might Promote Invasion and Metastasis of Colorectal Cancer via Decreasing Adhesion and Inducing Epithelial–Mesenchymal Transition

B‑cell translocation 1 gene inhibits cellular metastasis‑associated behavior in breast cancer.

The effect of BTG1 expression on proliferation, apoptosis and invasion of non-small cell lung cancer cells

PBRM1 Regulates Proliferation and the Cell Cycle in Renal Cell Carcinoma Through a Chemokine/chemokine Receptor Interaction Pathway

The roles of BTG1 mRNA expression in cancers: A bioinformatics analysis

Btg1 Expression Correlates With The Pathogenesis And Progression Of Ovarian Carcinomas

BRG1 promotes progression of B-cell acute lymphoblastic leukemia by disrupting PPP2R1A transcription

PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma

GLUD1 Suppresses Renal Tumorigenesis and Development Via Inhibiting PI3K/Akt/mTOR Pathway.

TRIM65 promotes renal cell carcinoma through ubiquitination and degradation of BTG3

PRMT5 Promotes Cell Proliferation by Inhibiting BTG2 Expression Via the ERK Signaling Pathway in Hepatocellular Carcinoma.

MiR-4295 Promotes Cell Growth in Bladder Cancer by Targeting BTG1.

The clinical significance and anti-tumor role of PRKG1 in bladder cancer